Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499117 | 0.82 | EGLN1 (0.47) | SCN9AEGLN1NPC1PTGDR2MAPT | |
| SCHEMBL2190049 | 0.77 | ALKBH2 (0.74) | EGLN1MAP4K4HPGDSALKBH2NPC1 | |
| SCHEMBL4481678 | 0.76 | HPGDS (0.51) | MAP4K4HPGDSALKBH2NPC1BTK | |
| SCHEMBL30132085 | 0.76 | HPGDS (0.51) | MAP4K4HPGDSALKBH2NPC1BTK | |
| SCHEMBL4484548 | 0.74 | SCN9A (0.57) | SCN9A | |
| SCHEMBL30573194 | 0.72 | MAP4K4 (0.44) | EGLN1MAP4K4HPGDSALKBH2CHEK2 | |
| SCHEMBL3107063 | 0.72 | EPHX2 (0.64) | EGLN1HPGDSALKBH2NPC1BTK | |
| SCHEMBL2688812 | 0.70 | CHEK2 (0.58) | SCN9AMAP4K4CHEK2MAPT | |
| SCHEMBL7846008 | 0.70 | EPHB4 (0.44) | EGLN1MAP4K4HPGDSALKBH2NPC1 | |
| SCHEMBL30978305 | 0.70 | BTK (0.48) | SCN9AEGLN1HPGDSALKBH2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1615895-A4 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| EP-1615895-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092140-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | SCN9A 78/4885EGLN1 3841/4885MAP4K4 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.